Momelotinib Yields Clinically Significant Improvement in Myelofibrosis
Significantly greater proportion of patients reported 50 percent or greater reduction in total symptom score with momelotinib versus danazol
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.